AXSOME THERAPEUTICS, INC. (AXSM) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.51B; Retained Earnings (Accumulated Deficit)USD $-1.42B; Stockholders' Equity Attributable to ParentUSD $83.30M.
- 2026-03-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.43B; Retained Earnings (Accumulated Deficit)USD $-1.37B; Stockholders' Equity Attributable to ParentUSD $54.59M.
- 2025-12-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.39B; Retained Earnings (Accumulated Deficit)USD $-1.31B; Stockholders' Equity Attributable to ParentUSD $88.30M.
- 2025-09-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.35B; Retained Earnings (Accumulated Deficit)USD $-1.28B; Stockholders' Equity Attributable to ParentUSD $73.73M.
AXSOME THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Additional Paid in Capital USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00K | $1.51B | $-1.42B | $83.30M | 3 month · $27.62M | (m) | (m) |
| 2026-03-31 | $5.00K | $1.43B | $-1.37B | $54.59M | 3 month · $23.91M | (m) | (m) |
| 2025-12-31 | $5.00K | $1.39B | $-1.31B | $88.30M | 12 month · $95.30M | (m) | (m) |
| 2025-09-30 | $5.00K | $1.35B | $-1.28B | $73.73M | 3 month · $23.44M | (m) | (m) |
| 2025-06-30 | $5.00K | $1.30B | $-1.23B | $73.08M | 3 month · $24.95M | (m) | (m) |
| 2025-03-31 | $5.00K | $1.24B | $-1.18B | $53.20M | 3 month · $23.65M | (m) | (m) |
| 2024-12-31 | $5.00K | $1.18B | $-1.12B | $57.02M | 12 month · $86.56M | (m) | (m) |
| 2024-09-30 | $5.00K | $1.14B | $-1.05B | $92.90M | 3 month · $21.99M | (m) | (m) |
| 2024-06-30 | $5.00K | $1.09B | $-983.27M | $102.85M | 3 month · $21.71M | (m) | (m) |
| 2024-03-31 | $5.00K | $1.05B | $-903.93M | $144.04M | 3 month · $20.53M | (m) | (m) |
| 2023-12-31 | $5.00K | $1.03B | $-835.57M | $190.98M | 12 month · $65.36M | 12 month · $1.64M | (m) |
| 2023-09-30 | $5.00K | $1.01B | $-736.92M | $269.51M | 3 month · $17.24M | (m) | (m) |
| 2023-06-30 | $5.00K | $953.52M | $-674.72M | $278.80M | 3 month · $15.92M | (m) | (m) |
| 2023-03-31 | $4.00K | $719.36M | $-607.55M | $111.81M | 3 month · $12.94M | 3 month · $1.01M | (m) |
| 2022-12-31 | $4.00K | $705.88M | $-596.33M | $109.56M | 12 month · $37.73M | 12 month · $826.00K | (m) |
| 2022-09-30 | $4.34K | $692.45M | $-535.09M | $157.36M | 3 month · $9.20M | (m) | (m) |
| 2022-06-30 | $3.99K | $505.47M | $-490.27M | $15.20M | 3 month · $10.16M | (m) | (m) |
| 2022-03-31 | $3.89K | $463.53M | $-448.83M | $14.70M | 3 month · $7.60M | (m) | (m) |
| 2021-12-31 | $3.78K | $424.83M | $-409.20M | $15.63M | 12 month · $20.80M | (m) | (m) |
| 2021-09-30 | $3.77K | $417.94M | $-375.22M | $42.72M | 3 month · $5.73M | (m) | (m) |
| 2021-06-30 | $3.77K | $411.77M | $-340.34M | $71.44M | 3 month · $5.46M | (m) | (m) |
| 2021-03-31 | $3.76K | $404.35M | $-308.06M | $96.29M | 3 month · $3.73M | (m) | (m) |
| 2020-12-31 | $3.74K | $392.59M | $-278.80M | $113.79M | 12 month · $14.76M | (m) | (m) |
| 2020-09-30 | $3.73K | (m) | $-249.63M | $135.26M | 3 month · $2.87M | (m) | $384.89M |
| 2020-06-30 | $3.73K | (m) | $-226.71M | $154.24M | 3 month · $4.15M | (m) | $380.95M |
| 2020-03-31 | $3.71K | (m) | $-208.38M | $156.16M | 3 month · $2.13M | (m) | $364.53M |
| 2019-12-31 | $3.69K | $354.61M | $-175.90M | $178.72M | 12 month · $6.12M | (m) | $354.61M |
| 2019-09-30 | $3.45K | (m) | $-151.09M | $6.82M | 3 month · $1.16M | (m) | $157.91M |
| 2019-06-30 | $3.43K | (m) | $-131.95M | $24.28M | 3 month · $888.56K | (m) | $156.23M |
| 2019-03-31 | $3.33K | (m) | $-118.19M | $17.37M | 3 month · $1.26M | (m) | $135.56M |
| 2018-12-31 | $3.01K | (m) | $-107.55M | $937.92K | 12 month · $1.75M | (m) | $108.49M |
| 2018-09-30 | $2.68K | (m) | $-97.95M | $742.76K | 3 month · $392.67K | (m) | $98.69M |
| 2018-06-30 | $2.62K | (m) | $-89.67M | $7.01M | 3 month · $474.66K | (m) | $96.68M |
| 2018-03-31 | $2.56K | (m) | $-81.39M | $12.59M | 3 month · $534.57K | (m) | $93.97M |
| 2017-12-31 | $2.55K | (m) | $-76.58M | $16.72M | 12 month · $2.07M | (m) | $93.30M |
| 2017-09-30 | $2.37K | (m) | $-69.15M | $16.84M | (m) | (m) | $85.99M |
| 2017-06-30 | $2.36K | (m) | $-62.72M | $22.75M | (m) | (m) | $85.47M |
| 2017-03-31 | $2.35K | (m) | $-55.64M | $29.28M | (m) | (m) | $84.91M |
| 2016-12-31 | $1.92K | (m) | $-47.64M | $21.57M | 12 month · $2.03M | 12 month · $264.39K | $69.21M |
| 2016-09-30 | $1.92K | (m) | $-40.31M | $28.18M | (m) | (m) | $68.49M |
| 2016-06-30 | $1.92K | (m) | $-33.12M | $34.90M | (m) | (m) | $68.02M |
| 2016-03-31 | $1.92K | (m) | $-26.31M | $41.23M | (m) | (m) | $67.54M |
| 2015-12-31 | $1.92K | (m) | $-20.44M | $46.44M | 12 month · $803.28K | 12 month · $244.77K | $66.88M |
| 2014-12-31 | (m) | (m) | (m) | $-3.20M | 12 month · $376.81K | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | $-2.03M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |